IMPACT OF PLASMA LP-PLA2 ACTIVITY LEVEL ON THE PROGRESSION OF AORTIC STENOSIS: THE PROGRESSA STUDY  by Capoulade, Romain et al.
Valvular Heart Disease
A1921
JACC April 1, 2014
Volume 63, Issue 12
Impact of plasma lp-pla2 actIvIty level on the progressIon of aortIc stenosIs: the 
progressa study
Moderated Poster Contributions
Hall C
Saturday, March 29, 2014, 10:30 a.m.-10:45 a.m.
Session Title: Valvular Heart Disease I
Abstract Category: 28. Valvular Heart Disease: Clinical
Presentation Number: 1133M-368C
Authors: Romain Capoulade, Ablajan Mahmut, Lionel Tastet, Marie Arsenault, Élisabeth Bédard, Jean Dumesnil, Jean-Pierre Despres, Patrick 
Mathieu, Philippe Pibarot, CRIUCPQ, Quebec, Canada
Background: Recently, we reported an association between plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and ectopic 
mineralization of the aortic valve (AV). The objective of this study was to examine the association between plasma Lp-PLA2 activity and the 
progression rate of aortic stenosis (AS). 
methods: 183 consecutive patients with AS and preserved LV ejection fraction were prospectively recruited in the PROGRESSA study. Patients 
underwent a Doppler-echocardiography annually and AS progression rate was assessed by the annualized increase in peak aortic jet velocity 
(Vpeak). 
results: The sample of 183 patients included 30% of women and mean age was 66±13 years. 74% of patients had hypertension, 67% 
dyslipidemia and 22% diabetes. Average Vpeak was 2.8±0.6 m/s. Over the 2.5±1.4 year follow up time, there was no difference in AS progression 
rate between patients with high versus low level of Lp-PLA2 activity (i.e. > vs. < 11.4 nmol/min/ml [median value]): annualized Vpeak=0.17±0.23 
vs. 0.12±0.18 m/s; p=0.14. However, there was an interaction (p=0.04) between baseline AS severity and Lp-PLA2 activity with respect to impact 
on AS progression. In the subset of patients with moderate or severe AS (i.e. Vpeak>3m/s; n=60), there was no association between Lp-PLA2 activity 
and AS progression rate (p=0.76), whereas in patients with mild AS (i.e. Vpeak<3m/s; n=123), a high level of Lp-PLA2 activity was associated with 
significantly faster AS progression rate (0.16±0.18 vs. 0.08±0.14 m/s; p=0.01). After adjustment for age, gender, hypertension, diabetes, creatinin, 
bicuspid AV, degree of AV calcification, and baseline Vpeak, Lp-PLA2 activity level remained independently associated with faster AS progression rate 
(p=0.02). Further adjustment for LDL-chol or statin did not alter this relationship (p=0.04 and p=0.02, respectively).
conclusion: This study indicate that elevated plasma Lp-PLA2 activity are associated with faster AS progression rate in patients with mild AS. These 
results suggest that Lp-PLA2 activity could be directly involved in the earlier stages of the development and progression of AS. These findings open 
new avenue for the treatment of AS. 
